(Q46964970)

26 December 2017

title

Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers (English)

1 reference

26 December 2017

1 reference

Desiree L Tomilo

1

1 reference

26 December 2017

Patrick F Smith

2

1 reference

26 December 2017

Abayomi B Ogundele

3

1 reference

26 December 2017

Robin Difrancesco

4

1 reference

26 December 2017

Charles S Berenson

5

1 reference

26 December 2017

Ellana Eberhardt

6

1 reference

26 December 2017

Edward Bednarczyk

7

1 reference

26 December 2017

Gene D Morse

8

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

26 December 2017

published in

Pharmacotherapy

1 reference

26 December 2017

volume

26

1 reference

26 December 2017

page(s)

341-346

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

https://api.crossref.org/works/10.1592%2FPHCO.26.3.341

1 reference

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.341

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.341

Lack of interaction between atazanavir and lansoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.341

Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.341

Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.341

Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.341

Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.341

Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.341

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.341

Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.3.341

21 January 2018

Identifiers

DOI

10.1592/PHCO.26.3.341

1 reference

26 December 2017

PubMed ID

16503713

1 reference

26 December 2017